Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Shareholder Director NominationsItem 5.08 — Shareholder Director Nominations.
On April 11, 2017, the board of directors, or the Board, of Eagle Pharmaceuticals, Inc., or the Company, approved June 20, 2017 as the date of the Company’s 2017 annual meeting of stockholders, or the Annual Meeting. The record date for the Annual Meeting will be April 25, 2017.
Qualified stockholder proposals (including proposals made to Rule 14a-8 or Rule 14a-18 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or in the manner contemplated by the Company’s Amended and Restated Bylaws, or the Bylaws) to be presented at the Annual Meeting and included in the Company’s proxy statement and form of proxy relating to that meeting must be received at the Company’s headquarters and addressed to the Company’s corporate secretary. Because the date of the Annual Meeting has been changed to a date that is more than 30 days earlier than the one-year anniversary date of the Company’s 2016 annual meeting of stockholders, in accordance with Rule 14a-18 and the Bylaws, to be timely, such proposal must be received no later than April 24, 2017. For inclusion in the Company’s proxy statement, proposals must comply with applicable Delaware law, the rules and regulations promulgated by the U.S. Securities and Exchange Commission, and the procedures set forth in the Bylaws.